Natasha Hernday
Director/Board Member bei ALPINE IMMUNE SCIENCES, INC.
Vermögen: - $ am 31.03.2024
Profil
Natasha A.
Hernday is an Independent Director at XOMA Corp.
and Alpine Immune Sciences, Inc. She is also the Chief Business Officer at Seagen Inc. Previously, she worked as the Director-Mergers, Acquisitions & Out-Partnering at Amgen, Inc. from 1994 to 2010 and as an Independent Director at PDL BioPharma, Inc. from 2019 to 2022.
Ms. Hernday holds an MBA from Pepperdine University and an undergraduate degree from the University of California, Santa Barbara.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
XOMA CORPORATION
-.--% | 18.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
| 02.01.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Natasha Hernday
| Unternehmen | Position | Beginn |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | 01.01.2011 |
| XOMA CORPORATION | Director/Board Member | 30.06.2020 |
| ALPINE IMMUNE SCIENCES, INC. | Director/Board Member | 10.12.2020 |
Ehemalige bekannte Positionen von Natasha Hernday
| Unternehmen | Position | Ende |
|---|---|---|
| PDL BIOPHARMA, INC. | Director/Board Member | 01.12.2022 |
| AMGEN INC. | Corporate Officer/Principal | 01.01.2010 |
Ausbildung von Natasha Hernday
| Pepperdine University | Masters Business Admin |
| University of California, Santa Barbara | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| XOMA CORPORATION | Health Technology |
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
